12:00 AM
 | 
Mar 03, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1)

Cardiovascular disease

INDICATION: Myocardial infarction (MI)

Mouse studies suggest inhibiting EGLN2 could help prevent cardiac injury in patients at risk of MI. In a mouse...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >